{"id":218080,"date":"2026-04-18T07:45:47","date_gmt":"2026-04-18T07:45:47","guid":{"rendered":"https:\/\/teknomers.com\/en\/the-medication-that-lowers-stroke-risk-for-those-who-have-experienced-one-currently-under-research\/"},"modified":"2026-04-18T07:45:49","modified_gmt":"2026-04-18T07:45:49","slug":"the-medication-that-lowers-stroke-risk-for-those-who-have-experienced-one-currently-under-research","status":"publish","type":"post","link":"https:\/\/teknomers.com\/en\/the-medication-that-lowers-stroke-risk-for-those-who-have-experienced-one-currently-under-research\/","title":{"rendered":"The Medication That Lowers Stroke Risk for Those Who Have Experienced One: Currently Under Research"},"content":{"rendered":"\n
\n

Asundexin: A Promising Drug in Stroke Prevention<\/h2>\n

The asundexin<\/b> drug, currently under investigation, has shown remarkable promise in reducing the risk of stroke for individuals who have recently suffered from either a stroke or a transient ischemic attack (TIA) of non-cardioembolic origin. This groundbreaking research hails from an extensive international study<\/b> conducted by McMaster University in Canada, with findings published in The New England Journal of Medicine<\/i>.<\/p>\n

Study Overview and Results<\/h3>\n

The trial involved 12,327 adults<\/b> from 37 countries, all selected within the first 72 hours following a non-cardioembolic stroke or TIA. Researchers compared the efficacy and safety of asundexin against standard antiplatelet therapy. Established treatments typically offer only a modest decrease in the risk of recurring strokes, and they come with the added risk of increased bleeding when used alone or in combination.<\/p>\n

The findings indicate that asundexin results in a 26% reduction<\/b> in stroke incidence compared to placebo, without increasing the risk of serious bleeding\u2014one of the major side effects of current treatments.<\/p>\n

Participant Details and Monitoring<\/h3>\n

The participants had an average age of 68 years, with 25% aged over 75. They were randomly administered either a daily dose of 50 mg of asundexin or a placebo, in conjunction with aspirin or other conventional antiplatelet medications. Of the participants, 95% had endured non-cardioembolic strokes, while the remainder had high-risk TIAs.<\/p>\n

Evaluation processes included monthly check-ups<\/b> after three months and subsequent quarterly evaluations. Notably, only 6.2% of those receiving the experimental drug suffered a second ischemic stroke, compared to 8.4% in the placebo group, demonstrating a relative risk reduction of 26%.<\/p>\n

Cardiovascular Events and Overall Impact<\/h3>\n

The study further highlights significant differences in serious cardiovascular events\u2014defined as strokes, heart attacks, or cardiovascular deaths. In the treatment group, 9.2% experienced such events, compared to 11.1% in the placebo cohort, showcasing a 17% decrease<\/b>. Notably, strokes that were disabling or fatal occurred in 2.1% of patients treated with asundexin, in contrast to 3% in the placebo group, marking a decrease of 31%.<\/p>\n

Mechanism of Action<\/h3>\n

Unique among anticoagulants, the mechanism of action for asundexin<\/b> focuses on the Factor XIa protein, crucial in forming harmful clots while also playing a role in the body\u2019s natural ability to stop bleeding. This innovative therapeutic target aims to balance effective clot prevention and the body’s essential capacity to stem hemorrhage.<\/p>\n

Expert Insights<\/h3>\n

Mike Sharma, principal investigator and senior scientist at the Population Health Research Institute (PHRI), emphasizes that after decades of effort, asundexin effectively reduced stroke incidence by 26%, a benefit consistent across various demographic factors. He notes that this achievement comes without the enhanced risk of serious bleeding seen in existing therapies.<\/p>\n

Co-principal investigator Ashkan Shoamanesh echoed this importance, asserting that the data brings hope for a safer method to prevent recurrent strokes\u2014something that both medical professionals and families have long sought.<\/p>\n

*With information from Europa Press<\/i><\/p>\n<\/div>\n


\n
General News – 2<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Asundexin: A Promising Drug in Stroke Prevention The asundexin drug, currently under investigation, has shown remarkable promise in reducing the risk of stroke for individuals who have recently suffered from either a stroke or a transient ischemic attack (TIA) of non-cardioembolic origin. This groundbreaking research hails from an extensive international study conducted by McMaster University […]<\/p>\n","protected":false},"author":1,"featured_media":218081,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[3336,2053,3917,729,1207,7942],"class_list":["post-218080","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-mazagine","tag-experienced","tag-lowers","tag-medication","tag-research","tag-risk","tag-stroke"],"_links":{"self":[{"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/posts\/218080","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/comments?post=218080"}],"version-history":[{"count":1,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/posts\/218080\/revisions"}],"predecessor-version":[{"id":218082,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/posts\/218080\/revisions\/218082"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/media\/218081"}],"wp:attachment":[{"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/media?parent=218080"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/categories?post=218080"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/tags?post=218080"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}